Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-arm Study of Moxetumomab Pasudotox in Pediatric Relapsed/Refractory B-cell ALL or Lymphoblastic Lymphoma
2012-003101-10Phase 2Completed
- Sponsor
- MedImmune
- Start
- Mar 2013
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of moxetumomab pasudotox in B cell acute lymphoblastic leukemia (B-ALL) and precursor B-lymphoblastic lymphoma (B-LBL), sponsored by MedImmune. Primary endpoint: Composite complete response (CRc). Started Mar 2013; status: completed.
02
Drugs
moxetumomab pasudotox
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)precursor B-lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on 2012-003101-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003101-10.